Literature DB >> 22341260

Modern radiation therapy techniques for pancreatic cancer.

Nicholas Trakul1, Albert C Koong, Peter G Maxim, Daniel T Chang.   

Abstract

Radiation therapy is a rapidly evolving field, and recent technical advances have spurred an increasing number of new treatments as well as marked improvements in previously existing treatments. Despite a growing body of published evidence demonstrating that radiotherapy for the treatment of pancreatic cancer is improving in efficacy and safety, the ultimate effect on patient outcomes remains to be seen. It is an unfortunate fact that the majority of pancreatic cancer patients will ultimately have metastases and succumb to distant disease. Thus, improvements in local tumor control engendered by these recent advances will have little impact on overall survival without the coincident development of better systemic treatment regimens.

Entities:  

Mesh:

Year:  2011        PMID: 22341260     DOI: 10.1016/j.gtc.2011.12.011

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  4 in total

Review 1.  Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist.

Authors:  Samuel K Kim; Cheng-Chia Wu; David P Horowitz
Journal:  J Gastrointest Oncol       Date:  2016-06

2.  Antibody against CD44s inhibits pancreatic tumor initiation and postradiation recurrence in mice.

Authors:  Ling Li; Xinbao Hao; Jun Qin; Wenhua Tang; Fengtian He; Amber Smith; Min Zhang; Diane M Simeone; Xiaotan T Qiao; Zhi-Nan Chen; Theodore S Lawrence; Liang Xu
Journal:  Gastroenterology       Date:  2014-01-05       Impact factor: 22.682

3.  Dosimetric and clinical toxicity comparison of critical organ preservation with three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and RapidArc for the treatment of locally advanced cancer of the pancreatic head.

Authors:  L Jin; R Wang; S Jiang; J Yue; T Liu; X Dou; K Zhu; R Feng; X Xu; D Chen; Y Yin
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

4.  Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma.

Authors:  Zhaoyan Qiu; Yi Chu; Bing Xu; Qian Wang; Mingzuo Jiang; Xiaowei Li; Gang Wang; Pengfei Yu; Guoxiao Liu; Hua Wang; Huijie Kang; Jiayu Liu; Yu Zhang; Jian-Ping Jin; Kaichun Wu; Jie Liang
Journal:  Oncotarget       Date:  2017-05-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.